From Retrospective Analysis of Patients with Undifferentiated Spondyloarthritis (SpA) to Analysis of Prospective Cohorts and Detection of Axial and Peripheral SpA

Burgos‐Vargas, Rubén; Casasola-Vargas, Julio

doi:10.3899/jrheum.100413

Cited by 13 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…USpA are frequently characterized by isolated episodes of peripheral arthritis and enthesitis, axial or back pain and by a lower incidence of HLA-B27 versus AS [24]. In our present study, incidence of HLA-B27 was 37.5% in patients with USpA.…”

Section: Discussionsupporting

confidence: 50%

Assessment of Fatigue in Undifferentiated Spondyloarthritis (USpA)

Alkan¹,

Fidan²,

Atalay³

et al. 2014

OJRA

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 50%

Assessment of Fatigue in Undifferentiated Spondyloarthritis (USpA)

Alkan¹,

Fidan²,

Atalay³

et al. 2014

OJRA

View full text Add to dashboard Cite

“…The diseases and conditions that constitute the SpA group are defined by signs, symptoms, and radiographic findings and are consisted of ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and a subgroup of undifferentiated forms [168, 169]. The main clinical feature of SpA is inflammation of the axial spine.…”

Section: Perspectivesmentioning

confidence: 99%

Defects in Tendon, Ligament, and Enthesis in Response to Genetic Alterations in Key Proteoglycans and Glycoproteins: A Review

Juneja

Veillette

2013

Arthritis

View full text Add to dashboard Cite

This review summarizes the genetic alterations and knockdown approaches published in the literature to assess the role of key proteoglycans and glycoproteins in the structural development, function, and repair of tendon, ligament, and enthesis. The information was collected from (i) genetically altered mice, (ii) in vitro knockdown studies, (iii) genetic variants predisposition to injury, and (iv) human genetic diseases. The genes reviewed are for small leucine-rich proteoglycans (lumican, fibromodulin, biglycan, decorin, and asporin); dermatan sulfate epimerase (Dse) that alters structure of glycosaminoglycan and hence the function of small leucine-rich proteoglycans by converting glucuronic to iduronic acid; matricellular proteins (thrombospondin 2, secreted phosphoprotein 1 (Spp1), secreted protein acidic and rich in cysteine (Sparc), periostin, and tenascin X) including human tenascin C variants; and others, such as tenomodulin, leukocyte cell derived chemotaxin 1 (chondromodulin-I, ChM-I), CD44 antigen (Cd44), lubricin (Prg4), and aggrecan degrading gene, a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5 (Adamts5). Understanding these genes represents drug targets for disrupting pathological mechanisms that lead to tendinopathy, ligamentopathy, enthesopathy, enthesitis and tendon/ligament injury, that is, osteoarthritis and ankylosing spondylitis.

show abstract

“…The initial descriptions of u-SpA dated back to 1983 and 1984 [35,36] and consisted of patients fulfilling the Amor, et al [37] as well as the European Spondylarthropathy Study Group (ESSG) [38] classification criteria for SpA, but not fulfilling criteria for AS or the specific diagnostic features of ReA, PsA, Crohn’s disease, and ulcerative colitis. Besides IBP, peripheral arthritis and enthesitis have been prominent features at onset in patients with u-SpA [39,40]. In retrospect, most patients with u-SpA fulfill AS criteria within five to ten years after onset (Figure 1) [41-49].…”

Section: Reviewmentioning

confidence: 99%

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist

Burgos‐Vargas

2012

Pediatr Rheumatol

Self Cite

View full text Add to dashboard Cite

This review refers to the origin and current state of the assessment of the SpondyloArthritis International Society (ASAS) criteria for the classification of axial and peripheral spondyloarthritis (SpA) and the possible implications in the pediatric population. The ASAS criteria evolved from the idea that the earlier the recognition of patients with ankylosing spondylitis, the better the efficacy of tumor necrosis factor blockers. Strategies included the development of new concepts, definitions, and techniques for the study of clinical signs and symptoms. Of relevance, the new definition of inflammatory back pain (IBP) and the introduction of sacroiliitis by magnetic resonance imaging represented the most important advance in the early identification of AS in the “pre-radiographic stage” of the disease. AS is considered in this paper as a disease continuum with symptoms depending on age at onset. The application of those specific strategies in children and adolescents with SpA seems limited because the most important manifestation in the early stage of disease is not IBP, but peripheral arthritis and enthesitis. In this instance, the logical approach to juvenile onset SpA according to ASAS criteria should not be through the axial criteria but rather the peripheral set of criteria.

show abstract

From Retrospective Analysis of Patients with Undifferentiated Spondyloarthritis (SpA) to Analysis of Prospective Cohorts and Detection of Axial and Peripheral SpA

Cited by 13 publications

References 33 publications

Assessment of Fatigue in Undifferentiated Spondyloarthritis (USpA)

Assessment of Fatigue in Undifferentiated Spondyloarthritis (USpA)

Defects in Tendon, Ligament, and Enthesis in Response to Genetic Alterations in Key Proteoglycans and Glycoproteins: A Review

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist

Contact Info

Product

Resources

About